Set-point theory suggests that your body defends a preferred weight range
CrossRefPubMedDirect Link Salmanzadeh, M., 2011
Injectable semaglutide currently dominates the segment, accounting for approximately 72% of total adoption due to its proven efficacy, once-weekly dosing convenience, and strong clinical outcomes in both glycemic control and weight reduction
Starting at $149 per month, PlexusDx semaglutide reaches all 50 states without insurance requirements, making weekly injections accessible and affordable
In RUO content, documentation should describe records and analytical evidence, not results for a person, animal, clinical setting, or product-use scenario